0QZU Panoramica delle azioni Vertex Pharmaceuticals Incorporated, società di biotecnologie, è impegnata nello sviluppo e nella commercializzazione di terapie per il trattamento della fibrosi cistica (FC). Maggiori dettagli
Premi Analisi del rischio Non sono stati rilevati rischi per 0QZU dai nostri controlli di rischio.
Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Vertex Pharmaceuticals Incorporated Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Vertex Pharmaceuticals Prezzi storici delle azioni Prezzo attuale dell'azione US$405.26 Massimo di 52 settimane US$519.66 Minimo di 52 settimane US$378.12 Beta 0.37 Variazione di 1 mese -11.80% Variazione a 3 mesi -10.57% Variazione di 1 anno -2.79% Variazione a 3 anni 82.30% Variazione a 5 anni 77.26% Variazione dall'IPO 266.72%
Notizie e aggiornamenti recenti
Vertex Pharmaceuticals Incorporated Announces U.S. FDA Approval for Trialta® (elexacaftor/ivacaftor andivacaftor) to Include Additional Non-F508del TrialKAFTA-Responsive Variants Dec 21
Vertex Pharmaceuticals Incorporated Announces Results from Phase 2 Study of Suzetrigine for Treatment of Painful Lumbosacral Radiculopathy Dec 19
Vertex Pharmaceuticals Incorporated Presents Positive Long-Term Data on Casgevy at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update Dec 09
Third quarter 2024 earnings released: EPS: US$4.05 (vs US$4.01 in 3Q 2023) Nov 05
Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024 Nov 05
Vertex Pharmaceuticals Incorporated to Report Q3, 2024 Results on Nov 04, 2024 Oct 11 Vedi altri aggiornamenti
Vertex Pharmaceuticals Incorporated Announces U.S. FDA Approval for Trialta® (elexacaftor/ivacaftor andivacaftor) to Include Additional Non-F508del TrialKAFTA-Responsive Variants Dec 21
Vertex Pharmaceuticals Incorporated Announces Results from Phase 2 Study of Suzetrigine for Treatment of Painful Lumbosacral Radiculopathy Dec 19
Vertex Pharmaceuticals Incorporated Presents Positive Long-Term Data on Casgevy at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update Dec 09
Third quarter 2024 earnings released: EPS: US$4.05 (vs US$4.01 in 3Q 2023) Nov 05
Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024 Nov 05
Vertex Pharmaceuticals Incorporated to Report Q3, 2024 Results on Nov 04, 2024 Oct 11
Second quarter 2024 earnings released: US$13.92 loss per share (vs US$3.55 profit in 2Q 2023) Aug 02
Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024 Aug 02
Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-To-Severe Acute Pain Jul 31 Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Marketing Authorization for Trikafa® for People with Cystic Fibrosis Aged 2 Years and Older with Certain Rare Mutations Jul 16
Vertex Pharmaceuticals Incorporated to Report Q2, 2024 Results on Aug 01, 2024
Vertex Pharmaceuticals, Inc. Announces Positive Results from Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Jun 22
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders. May 21
Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director May 16
Vertex Pharmaceuticals Incorporated Re-Iterates Earnings Guidance for the Full Year 2024 May 08
First quarter 2024 earnings released: EPS: US$4.26 (vs US$2.72 in 1Q 2023) May 07
Vertex Pharmaceuticals Announces European Commission Approval for KALYDECO to Treat Infants with Cystic Fibrosis Ages 1 Month and Older Apr 27
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion. Apr 11
Vertex Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 06, 2024 Apr 10
Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 15, 2024 Apr 05 Vertex Pharmaceuticals Incorporated Announces New Drug Submission for Exagamglogene Autotemcel (Exa-Cel) Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older Feb 23
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Feb 13
Vertex Pharmaceuticals Incorporated Announces Positive Results from Pivotal Trials of Vanza Triple Combination Treatment for Cystic Fibrosis Feb 07
Vertex Pharmaceuticals Incorporated Provides Product Revenue Guidance for the Full Year 2024 Feb 06
Full year 2023 earnings released: EPS: US$14.05 (vs US$12.97 in FY 2022) Feb 06
Vertex Announces Positive Results from the VX-548 Phase 3 Program for the Treatment of Moderate-To-Severe Acute Pain Jan 30
Vertex Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 05, 2024 Jan 18
Vertex Pharmaceuticals Incorporated Announces US FDA Approval of CASGEVY™ (Exagamglogene Autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia Jan 17
Vertex Pharmaceuticals Incorporated Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Kingdom of Saudi Jan 10
Vertex Pharmaceuticals Incorporated Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Dec 16
Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy Dec 14 CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States
Vertex Pharmaceuticals Incorporated Appoints Nancy Thornberry to Its Board of Directors as an Independent Director Dec 06
Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older Nov 30
Vertex Pharmaceuticals Incorporated Announces European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5 Nov 24
Vertex Pharmaceuticals Incorporated Announces United Kingdom Medicines and Healthcare Products Regulatory Agency Granted Conditional Marketing Authorization for CASGEVY Nov 17
Third quarter 2023 earnings released: EPS: US$4.01 (vs US$3.63 in 3Q 2022) Nov 08
Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Market Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With at Least One F508del Mutation Oct 18
Vertex Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 06, 2023 Oct 11
Vertex Pharmaceuticals Incorporated Appoints Michel Lagarde to Its Board of Directors Oct 06
Vertex Pharmaceuticals Incorporated Receives Chmp Positive Opinion for Kaftrio® (Ivacaftor/Tezacaftor/Elexacaftor) in Combination with Ivacaftor for Children with Cystic Fibrosis Ages 2 Through 5 Sep 16
Vertex Pharmaceuticals Incorporated Appoints E. Morrey Atkinson, Ph.D., as Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations Aug 30
Vertex Pharmaceuticals Incorporated Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine Aug 04
Second quarter 2023 earnings released: EPS: US$3.55 (vs US$3.17 in 2Q 2022) Aug 02
Vertex Pharmaceuticals Incorporated Announces European Commission Approval for ORKAMBI® (Lumacaftor/Ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 1 to <2 Years Old Jul 06
Insufficient new directors Jul 01
Vertex Pharmaceuticals Incorporated Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions Jun 24
Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Jun 10
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Jun 09
First quarter 2023 earnings released: EPS: US$2.72 (vs US$2.99 in 1Q 2022) May 03
Full year 2022 earnings released: EPS: US$12.97 (vs US$9.09 in FY 2021) Feb 08
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) announces an Equity Buyback for $3,000 million worth of its shares. Feb 08
Vertex Pharmaceuticals Incorporated to Report Q4, 2022 Results on Feb 07, 2023 Jan 18
Vertex Pharmaceuticals Incorporated Announces to Present New Data on its Portfolio of Cystic Fibrosis Medicines at 2022 North American Cystic Fibrosis Conference Nov 04
Third quarter 2022 earnings released: EPS: US$3.63 (vs US$3.30 in 3Q 2021) Oct 28
Vertex Pharmaceuticals Incorporated Revises Revenue Guidance for the Fiscal 2022 Oct 28
Vertex Pharmaceuticals Incorporated to Report Q3, 2022 Results on Oct 27, 2022 Oct 14
Vertex Pharmaceuticals Incorporated Advances Program Targeting Alpha-1 Antitrypsin Deficiency Oct 12
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022 Sep 28
Vertex Pharmaceuticals Incorporated Appoints Jonathan Biller as Chief Legal Officer, Effective September 19, 2022 Sep 10
Vertex Pharmaceuticals Incorporated Appoints Jonathan Biller as Chief Legal Officer, Effective September 19, 2022 Sep 09
Vertex Announces U.S. FDA Approval for Orkambi® (Lumacaftor/Ivacaftor) in Children with Cystic Fibrosis Ages 12 to <24 Months Sep 03
Second quarter 2022 earnings released: EPS: US$3.17 (vs US$0.26 in 2Q 2021) Aug 05
Vertex Pharmaceuticals Incorporated Reports Unaudited Intangible Asset Impairment Charge for the Three Months Ended June 30, 2022 Aug 05
Vertex Advances VX-548 in Acute and Neuropathic Pain Jul 23
Vertex Pharmaceuticals Incorporated to Report Q2, 2022 Results on Aug 04, 2022 Jul 19
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into a definitive agreement to acquire ViaCyte, Inc. from Sanderling Ventures, RA Capital Management, L.P., The Invus Group, LLC, Asymmetry Ventures LLC and others for approximately $320 million. Jul 13
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into a definitive agreement to acquire ViaCyte, Inc. from Sanderling Ventures, RA Capital Management, L.P., The Invus Group, LLC, Asymmetry Ventures LLC and others for approximately $320 million. Jul 12
Vertex Announces FDA Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes Jul 06
Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference Jun 11
Vertex Pharmaceuticals Incorporated Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA Jun 09
Vertex Pharmaceuticals Incorporated to Present New Data on VX-880 Clinical Trial Jun 01
Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million. May 25
Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million. May 24
Vertex Pharmaceuticals Incorporated Elects Suketu Upadhyay as Independent Director May 19
First quarter 2022 earnings released: EPS: US$2.99 (vs US$2.52 in 1Q 2021) May 06
Vertex Pharmaceuticals Incorporated Reiterates Earning Guidance for 2022 May 06
Vertex Pharmaceuticals Incorporated to Report Q1, 2022 Results on May 05, 2022 Apr 22
Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Marketing Authorization for TRIKAFTA in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation Apr 21
Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 18, 2022 Apr 08
Vertex Pharmaceuticals Incorporated Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain Apr 01
Vertex Pharmaceuticals Incorporated Announces Reimbursement Agreement in Australia for TRIKAFTA Mar 28
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Jan 27
Vertex Pharmaceuticals Incorporated Provides Full Year 2022 Financial Guidance Jan 27
Vertex Pharmaceuticals Incorporated announces European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) Jan 12
Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis Dec 02
Third quarter 2021 earnings released: EPS US$3.30 (vs US$2.56 in 3Q 2020) Nov 03
Vertex Pharmaceuticals Incorporated Announces Its Supplement to a New Drug Submission for PrKALYDECO Sep 24
Vertex Pharmaceuticals Incorporated Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People With Cystic Fibrosis Aug 27
CEO, President & Director recently bought US$2.0m worth of stock Aug 25
Lead Independent Director recently bought US$3.0m worth of stock Aug 05
Second quarter 2021 earnings released: EPS US$0.26 (vs US$3.23 in 2Q 2020) Jul 31
Vertex Pharmaceuticals Incorporated Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain Jul 20
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) announces an Equity Buyback for $1,500 million worth of its shares. Jun 25 Rendimenti per gli azionisti 0QZU GB Biotechs GB Mercato 7D -1.1% 3.3% 1.3% 1Y -2.8% -23.4% 4.3%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 0QZU ha superato il UK Biotechs che ha restituito -23.4 % nell'ultimo anno.
Rendimento vs Mercato: 0QZU ha avuto una performance inferiore al mercato UK che ha registrato un rendimento 4.3 % nell'ultimo anno.
Volatilità dei prezzi Is 0QZU's price volatile compared to industry and market? 0QZU volatility 0QZU Average Weekly Movement 5.3% Biotechs Industry Average Movement 9.8% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.5% 10% least volatile stocks in GB Market 2.6%
Prezzo delle azioni stabile: 0QZU non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 5% ) di 0QZU è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 1989 5,400 Reshma Kewalramani www.vrtx.com
Vertex Pharmaceuticals Incorporated, società di biotecnologie, è impegnata nello sviluppo e nella commercializzazione di terapie per il trattamento della fibrosi cistica (FC). L'azienda commercializza TRIKAFTA/KAFTRIO per le persone affette da fibrosi cistica con almeno una mutazione F508del a partire dai 2 anni di età; SYMDEKO/SYMKEVI per le persone affette da fibrosi cistica a partire dai 6 anni di età; ORKAMBI per i pazienti affetti da fibrosi cistica a partire da 1 anno di età; e KALYDECO per il trattamento dei pazienti affetti da fibrosi cistica a partire da 1 anno di età con ivacaftor. La pipeline dell'azienda comprende VX-522, un farmaco terapeutico a base di mRNA CFTR progettato per trattare la causa alla base della FC, che è in fase di sperimentazione clinica di Fase 1; VX-548, un farmaco non oppioide per il trattamento del dolore acuto e neuropatico, che è in fase di sperimentazione clinica di Fase 3; Exa-cel, per il trattamento della malattia a cellule falciformi e della beta-talassemia trasfusione-dipendente, che è in fase di sperimentazione clinica di Fase 2/3.
Mostra di più Vertex Pharmaceuticals Incorporated Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Vertex Pharmaceuticals con la sua capitalizzazione di mercato? 0QZU statistiche fondamentali Capitalizzazione di mercato US$103.71b Guadagni(TTM ) -US$479.80m Ricavi(TTM ) US$10.63b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 0QZU Conto economico (TTM ) Ricavi US$10.63b Costo del fatturato US$4.93b Profitto lordo US$5.69b Altre spese US$6.17b Guadagni -US$479.80m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -1.86 Margine lordo 53.59% Margine di profitto netto -4.52% Rapporto debito/patrimonio netto 0%
Come si è comportato 0QZU nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/01/02 07:27 Prezzo dell'azione a fine giornata 2025/01/02 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Vertex Pharmaceuticals Incorporated è coperta da 75 analisti. 32 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Jasper Hellweg Argus Research Company Brian Skorney Baird Ishan Majumdar Baptista Research
Mostra 72 altri analisti 
